Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Irish Journal of Medical Science (1971 -)
Published in: Irish Journal of Medical Science (1971 -) 3/2018

01-08-2018 | Review Article

MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective

Authors: Alexis M. Cahalane, Hugh Kearney, Yvonne M. Purcell, Christopher McGuigan, Ronan P. Killeen

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2018

Login to get access

Abstract

Magnetic resonance imaging (MRI) plays an integral role in the management of multiple sclerosis (MS), from both diagnostic and therapeutic perspectives. This 2-part review aims to detail the evolving and expanding role of MRI for both radiologists and neurologists. In this article, we discuss the diagnostic criteria for MS relevant to radiologists, as well as its varying imaging manifestations. The role of MRI in therapeutic modification and complications are discussed.
Literature
1.
2.
Wattjes MP, Steenwijk MD, Stangel M (2015) MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol 25(Suppl 2):157–165CrossRefPubMed
3.
Ge Y (2006) Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 27(6):1165–1176PubMed
4.
Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis––the plaque and its pathogenesis. N Engl J Med 354(9):942–955CrossRefPubMed
5.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral
6.
Cotton F, Weiner HL, Jolesz FA, Guttmann CR (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60(4):640–646CrossRefPubMed
7.
Rovira A, Wattjes MP, Tintore M, Tur C, Yousry TA, Sormani MP, De Stefano N, Filippi M, Auger C, Rocca MA, Barkhof F, Fazekas F, Kappos L, Polman C, Miller D, Montalban X (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11(8):471–482CrossRefPubMed
8.
Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D (2016) Revised recommendations of the consortium of MS centers task force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 37(3):394–401CrossRefPubMed
9.
Wattjes MP, Rovira A, Miller D, Yousry TA, Sormani MP, de Stefano MP, Tintore M, Auger C, Tur C, Filippi M, Rocca MA, Fazekas F, Kappos L, Polman C, Frederik B, Xavier M (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis––establishing disease prognosis and monitoring patients. Nat Rev Neurol 11(10):597–606PubMed
10.
11.
12.
van Munster CE, Jonkman LE, Weinstein HC, Uitdehaag BM, Geurts JJ (2015) Gray matter damage in multiple sclerosis: impact on clinical symptoms. Neuroscience 303:446–461CrossRefPubMed
13.
Calabrese M, Filippi M, Gallo P (2010) Cortical lesions in multiple sclerosis. Nat Rev Neurol 6(8):438–444CrossRefPubMed
14.
Calabrese M, Castellaro M (2017) Cortical gray matter MR imaging in multiple sclerosis. Neuroimaging Clin N Am 27(2):301–312CrossRefPubMed
15.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11):2705–2712CrossRefPubMed
16.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50(3):389–400CrossRefPubMed
17.
Calabrese M, De Stefano N, Atzori M, Bernardi V, Mattisi I, Barachino L, Morra A, Rinaldi L, Romualdi C, Perini P, Battistin L, Gallo P (2007) Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 64(10):1416–1422CrossRefPubMed
18.
Sethi V, Yousry TA, Muhlert N, Ron M, Golay X, Wheeler-Kingshott C, Miller DH, Chard DT (2012) Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI. J Neurol Neurosurg Psychiatry 83(9):877–882CrossRefPubMed
19.
Calabrese M, Rocca MA, Atzori M, Mattisi I, Bernardi V, Favaretto A, Barachino L, Romualdi C, Rinaldi L, Perini P, Gallo P, Filippi M (2009) Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 72(15):1330–1336CrossRefPubMed
20.
Nelson F, Datta S, Garcia N, Rozario NL, Perez F, Cutter G, Narayana PA, Wolinsky JS (2011) Intracortical lesions by 3T magnetic resonance imaging and correlation with cognitive impairment in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, Engl) 17(9):1122–1129CrossRef
21.
Jonkman LE, Klaver R, Fleysher L, Inglese M, Geurts JJ (2015) Ultra-high-field MRI visualization of cortical multiple sclerosis lesions with T2 and T2*: a postmortem MRI and histopathology study. AJNR Am J Neuroradiol 36(11):2062–2067CrossRefPubMed
22.
Seewann A, Kooi EJ, Roosendaal SD, Pouwels PJ, Wattjes MP, van der Valk P, Barkhof F, Polman CH, Geurts JJ (2012) Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology 78(5):302–308CrossRefPubMed
23.
Geurts JJ, Bo L, Pouwels PJ, Castelijns JA, Polman CH, Barkhof F (2005) Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 26(3):572–577PubMed
24.
Kilsdonk ID, Jonkman LE, Klaver R, van Veluw SJ, Zwanenburg JJ, Kuijer JP, Pouwels PJ, Twisk JW, Wattjes MP, Luijten PR, Barkhof F, Geurts JJ (2016) Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. Brain 139(Pt 5):1472–1481CrossRefPubMed
25.
Gaitan MI, Shea CD, Evangelou IE, Stone RD, Fenton KM, Bielekova B, Massacesi L, Reich DS (2011) Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions. Ann Neurol 70(1):22–29CrossRefPubMedPubMedCentral
26.
Masdeu JC, Quinto C, Olivera C, Tenner M, Leslie D, Visintainer P (2000) Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 54(7):1427–1433CrossRefPubMed
27.
Bot JC, Barkhof F, Polman CH, Lycklama A, Nijeholt GJ, de Groot V, Bergers E, Ader HJ, Castelijns JA (2004) Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 62(2):226–233CrossRefPubMed
28.
Bermel RA, Naismith RT (2015) Using MRI to make informed clinical decisions in multiple sclerosis care. Curr Opin Neurol 28(3):244–249CrossRefPubMed
29.
Chen JJ, Carletti F, Young V, McKean D, Quaghebeur G (2016) MRI differential diagnosis of suspected multiple sclerosis. Clin Radiol 71(9):815–827CrossRefPubMed
30.
Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M (1995) Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195(3):725–732CrossRefPubMed
31.
Marques IB, Matias F, Silva ED, Cunha L, Sousa L (2014) Risk of multiple sclerosis after optic neuritis in patients with normal baseline brain MRI. J Clin Neurosci 21(4):583–586CrossRefPubMed
32.
Petzold A, Wattjes MP, Costello F, Flores-Rivera J, Fraser CL, Fujihara K, Leavitt J, Marignier R, Paul F, Schippling S, Sindic C, Villoslada P, Weinshenker B, Plant GT (2014) The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 10(8):447–458CrossRefPubMed
33.
Hickman SJ, Brierley CM, Brex PA, MacManus DG, Scolding NJ, Compston DA, Miller DH (2002) Continuing optic nerve atrophy following optic neuritis: a serial MRI study. Mult Scler (Houndmills, Basingstoke, Engl) 8(4):339–342CrossRef
34.
Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, Morgenthau D, Lapierre Y (2013) Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 40(3):307–323CrossRefPubMed
35.
Cross AH, Naismith RT (2014) Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med 275(4):350–363CrossRefPubMed
36.
Wattjes MP, Barkhof F (2014) Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27(3):260–270CrossRefPubMed
37.
Bag AK, Cure JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. AJNR Am J Neuroradiol 31(9):1564–1576CrossRefPubMed
38.
Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M (2012) Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 72(5):779–787CrossRefPubMed
39.
Fraum TJ, Ludwig DR, Bashir MR, Fowler KJ (2017) Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 46(2):338–353CrossRefPubMed
40.
Beam AS, Moore KG, Gillis SN, Ford KF, Gray T, Steinwinder AH, Graham A (2017) GBCAs and risk for nephrogenic systemic fibrosis: a literature review. Radiol Technol 88(6):583–589PubMed
41.
Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet (Lond, Engl) 356(9234):1000–1001CrossRef
42.
Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR (2011) Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovascular imaging 4(11):1206–1216CrossRefPubMed
43.
Grobner T (2006) Gadolinium––a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21(4):1104–1108CrossRefPubMed
44.
Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17(9):2359–2362CrossRefPubMed
45.
Ramalho J, Ramalho M (2017) Gadolinium deposition and chronic toxicity. Magn Reson Imaging Clin N Am 25(4):765–778CrossRefPubMed
46.
Beckett KR, Moriarity AK, Langer JM (2015) Safe use of contrast media: what the radiologist needs to know. Radiographics 35(6):1738–1750CrossRefPubMed
47.
McDonald RJ, McDonald JS, Kallmes DF, Jentoft ME, Paolini MA, Murray DL, Williamson EE, Eckel LJ (2017) Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 285(2):546–554CrossRefPubMed
48.
Kanda T, Matsuda M, Oba H, Toyoda K, Furui S (2015) Gadolinium deposition after contrast-enhanced MR imaging. Radiology 277(3):924–925CrossRefPubMed
49.
Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A, Di Cesare E (2017) Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med. https://​doi.​org/​10.​1007/​s11547-017-0816-9
50.
European Medicines Agency (2017) EMA’s final opinion confirms restrictions on use of linear gadolinium agents in body scans. European Medicines Agency, London
Metadata
Title
MRI and multiple sclerosis––the evolving role of MRI in the diagnosis and management of MS: the radiologist’s perspective
Authors
Alexis M. Cahalane
Hugh Kearney
Yvonne M. Purcell
Christopher McGuigan
Ronan P. Killeen
Publication date
01-08-2018
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 3/2018
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-017-1714-9

Other articles of this Issue 3/2018

Irish Journal of Medical Science (1971 -) 3/2018 Go to the issue

Original Article

Epidemiological changes in rubella IgG antibody levels detected in antenatal women from a retrospective rubella seroprevalence study

Brief Report

Cognitive assessment of older adults in general practice: the collateral history

Original Article

Epidemiology of chronic hepatitis B virus in Ireland using routinely collected surveillance and administrative data, 2004–2014

Brief Report

From a direct oral anticoagulant to warfarin: reasons why patients switch

Review Article

Cadaveric simulation: a review of reviews

Original Article

Long-term endurance training increases serum cathepsin S levels in healthy female subjects
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits